Phio Pharmaceuticals Corp. (PHIO)
1.08
-0.03
(-2.70%)
USD |
NASDAQ |
Sep 04, 16:00
1.08
0.00 (0.00%)
After-Hours: 20:00
Phio Pharmaceuticals Research and Development Expense (Quarterly) : 3.082M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.082M |
| March 31, 2026 | 2.793M |
| December 31, 2025 | 1.477M |
| September 30, 2025 | 1.181M |
| June 30, 2025 | 1.074M |
| March 31, 2025 | 0.886M |
| December 31, 2024 | 0.985M |
| September 30, 2024 | 0.644M |
| June 30, 2024 | 0.866M |
| March 31, 2024 | 1.148M |
| December 31, 2023 | 1.007M |
| September 30, 2023 | 1.808M |
| June 30, 2023 | 1.383M |
| March 31, 2023 | 2.134M |
| December 31, 2022 | 1.614M |
| September 30, 2022 | 2.508M |
| June 30, 2022 | 1.304M |
| March 31, 2022 | 1.586M |
| December 31, 2021 | 1.795M |
| September 30, 2021 | 2.807M |
| June 30, 2021 | 1.663M |
| March 31, 2021 | 2.621M |
| December 31, 2020 | 1.178M |
| September 30, 2020 | 1.256M |
| June 30, 2020 | 0.779M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.218M |
| December 31, 2019 | 1.023M |
| September 30, 2019 | 1.042M |
| June 30, 2019 | 1.146M |
| March 31, 2019 | 1.089M |
| December 31, 2018 | 0.944M |
| September 30, 2018 | 0.838M |
| June 30, 2018 | 1.183M |
| March 31, 2018 | 1.361M |
| December 31, 2017 | 1.204M |
| September 30, 2017 | 1.49M |
| June 30, 2017 | 1.329M |
| March 31, 2017 | 1.347M |
| December 31, 2016 | 1.307M |
| September 30, 2016 | 1.464M |
| June 30, 2016 | 1.339M |
| March 31, 2016 | 1.305M |
| December 31, 2015 | 1.723M |
| September 30, 2015 | 1.734M |
| June 30, 2015 | 1.361M |
| March 31, 2015 | 2.107M |
| December 31, 2014 | 1.562M |
| September 30, 2014 | 1.459M |
| June 30, 2014 | 1.183M |
| March 31, 2014 | 1.476M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Imunon, Inc. | 1.465M |
| Agenus, Inc. | 14.76M |
| Amgen, Inc. | 1.868B |
| Anika Therapeutics, Inc. | 7.341M |
| BioCryst Pharmaceuticals, Inc. | 51.46M |